Development and Testing of an Identity Measure for Transgender and Gender Diverse Persons

摘要 有证据表明，变性人和不同性别(TGD)人群的风险显著增加 艾滋病毒和许多其他有害健康后果，主要是由于普遍暴露于性别-- 基于污名和歧视。这种偏见待遇被TGD人内在化为“身份非 验证：同一性理论中一种尚未被广泛采用的行为机制 由研究TGD人群的研究人员提出。这项研究将开发出第一个多维测量 使用认同理论的既定指标(例如，反映的身份标准)的TGD人员的性别认同 评价、突出度/突出度/承诺评级)和机制(例如，身份不核实、 身份纠正响应)。研究将分两个阶段进行，首先是#年的开发阶段 这些深度访谈是对一群有目的地抽样的TGD人员进行的，这些人平均分为 在六个月的过程中，年龄、艾滋病毒状况和性别认同(N=24名参与者)，然后是 为期六周，分析访谈数据并制定性别认同的初始维度 测量。六周的认知情况汇报访谈(n=6)将确认新的表面有效性 测量并允许对项目进行微调。这将结束开发阶段，并将开始 测试阶段(N=150)，在此阶段可以建立新测量的信度和效度，以及 可以对身份不核实如何与关键健康结果相关联进行测试。更深一层的 更细致入微地了解TGD人员如何看待自己，他们如何相信他人的看法 以及这两个结构之间的差异如何与HIV相关的结果和风险相关联 (包括接触艾滋病毒和对ART或PEP/PrEP的吸收/坚持)可能会产生新的假说， 更好的研究问题和干预受艾滋病毒影响最严重的人群之一的新方法 美国。

Abstract Evidence demonstrates that transgender and gender diverse (TGD) persons are at dramatically elevated risk for HIV and a number of other detrimental health outcomes largely as a result of pervasive exposure to gender- based stigma and discrimination. Such prejudicial treatment is internalized by TGD persons as “identity non- verification,” a well-established behavioral mechanism in Identity Theory which has yet to be broadly adopted by researchers studying TGD populations. This study would develop the first multidimensional measure of TGD persons' gender identities using Identity Theory's established metrics (e.g., identity standards, reflected appraisals, salience / prominence / commitment ratings) and mechanisms (e.g., identity non-verification, identity corrective responses). The study would occur in two stages, beginning with a Development Stage in which in-depth interviews are carried out with a purposively sampled group of TGD persons evenly split by age, HIV status, and gender identity (N = 24 participants each) over the course of six months followed by a period of six weeks to analyze the interview data and formulate initial dimensions of the gender identity measure. Six weeks of cognitive debriefing interviews (n = 6) would then confirm the face validity of the new measure and allow for fine-tuning of items. This would conclude the Development Stage and would commence the Testing Stage (N = 150), in which the reliability and validity of the new measure could be established, and a test of how identity non-verification is associated with critical health outcomes can be carried out. A deeper and more granular understanding of how TGD persons see themselves, how they believe other people see them, and how differences between these two constructs are associated with HIV-related outcomes and risks (including exposure to HIV and uptake/adherence to ART or PEP/PrEP) could generate new hypotheses, better research questions, and new methods of intervening in one of the populations most affected by HIV in the US.